Dr. Robert Whitfield recently sat down with Dr. Tanya Dempsey, a leading expert in mast cell activation syndrome, to discuss a condition that affects an estimated 17 to 20 percent of the population and is frequently missed by conventional medicine.
Mast cell activation syndrome, or MCAS, is a multi-system inflammatory condition in which immune cells called mast cells remain chronically overactivated. Patients experience symptoms involving the gut, skin, nervous system, cardiovascular system, and more, often leading to years of misdiagnosis.
In this conversation, Dr. Dempsey explains the top symptoms she sees in her clinic, the environmental and internal triggers that sustain mast cell activation, and the emerging connection between MCAS and breast implant illness. A recently published Danish study found that some implant patients mount an immune response resembling organ rejection, which aligns with Dr. Whitfield's clinical experience and his published biofilm research.
The article also covers the role of GLP-1 medications in directly calming mast cell activity, the link between insulin resistance and immune dysregulation, and practical lifestyle steps patients can take today.
Dr. Whitfield applies his SHARP framework to this discussion, connecting immune support, toxicity reduction, gut health, and hormonal balance to the MCAS clinical picture.
Find the full article at the link below and take a free health assessment at DrRobertWhitfield.com.
